Pancreatic Cancer Research

ResearcherUniversity of California, San FranciscoActive in the last 2 years

Grace Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4603-9448; OpenAlex author ID A5100403882. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
95
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity. Co-author DOI 10.1158/0008-5472.can-25-3126↗
  2. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09017-8↗
  3. Author Correction: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/s41591-023-02694-w↗
  4. nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer Co-author DOI 10.1101/2024.09.23.614610↗
  5. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15579-0↗
  6. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  7. Lysosomal retargeting of Myoferlin mitigates membrane stress to enable pancreatic cancer growth. Co-author DOI 10.1038/s41556-021-00644-7↗
  8. Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal Adenocarcinoma: Cross-continental and Cro… Last author DOI 10.1097/pas.0000000000001723↗
  9. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Co-author DOI 10.1038/s41586-020-2229-5↗
  10. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stra… Last author DOI 10.1097/pas.0000000000001152↗
  11. BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-17-0250↗
  12. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Co-author DOI 10.1002/jso.24375↗
  13. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/nm.4082↗
  14. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Co-author DOI 10.1101/gad.264861.115↗
  15. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncb2916↗
  16. Dicer regulates differentiation and viability during mouse pancreatic cancer initiation. Co-author DOI 10.1371/journal.pone.0095486↗
  17. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Co-author DOI 10.1016/j.ccr.2011.03.002↗
  18. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Co-author DOI 10.1038/nm.2344↗
  19. Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation. Co-author DOI 10.1073/pnas.1112047108↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthias Hebrok · 7 shared papers, 2011–2026 · strength 0.65
  2. David W. Dawson · 4 shared papers, 2014–2026 · strength 0.50
  3. Eric Andrew Collisson · 4 shared papers, 2011–2025 · strength 0.41
  4. Rushika Miriam Perera · 3 shared papers, 2020–2025 · strength 0.38
  5. Valerie Marie Weaver · 3 shared papers, 2016–2024 · strength 0.35
  6. Audrey M. Hendley · 2 shared papers, 2024–2026 · strength 0.35
  7. Andrew H. Ko · 4 shared papers, 2011–2024 · strength 0.35
  8. Margaret A. Tempero · 4 shared papers, 2011–2024 · strength 0.35
  9. Jen Jen Yeh · 2 shared papers, 2024–2025 · strength 0.33
  10. Sunhee S. Kim · 3 shared papers, 2016–2024 · strength 0.33
  11. Eric K. Nakakura · 3 shared papers, 2016–2024 · strength 0.33
  12. Kimberly Saunders Kirkwood · 3 shared papers, 2016–2024 · strength 0.33
  13. Rondell Patrell Graham · 2 shared papers, 2022–2026 · strength 0.32
  14. Claudio Luchini · 2 shared papers, 2022–2026 · strength 0.32
  15. Roberto Zoncu · 2 shared papers, 2021–2025 · strength 0.30
  16. Gilles Rademaker · 2 shared papers, 2021–2025 · strength 0.30
  17. Olca Baştürk · 2 shared papers, 2021–2022 · strength 0.27
  18. Deepti Dhall · 2 shared papers, 2021–2022 · strength 0.27
  19. Kee‐Taek Jang · 2 shared papers, 2021–2022 · strength 0.27
  20. Daniela S. Allende · 2 shared papers, 2021–2022 · strength 0.27
  21. Volkan N. Adsay · 2 shared papers, 2021–2022 · strength 0.27
  22. Jiaqi Shi · 2 shared papers, 2021–2022 · strength 0.27
  23. Nilotpal Roy · 3 shared papers, 2014–2024 · strength 0.24
  24. Alex Barrett · 2 shared papers, 2016–2024 · strength 0.20
  25. Hanane Laklai · 2 shared papers, 2016–2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.